64 related articles for article (PubMed ID: 16208410)
21. Calciphylaxis: a review.
Magro CM; Simman R; Jackson S
J Am Col Certif Wound Spec; 2010 Dec; 2(4):66-72. PubMed ID: 24527153
[TBL] [Abstract][Full Text] [Related]
22. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms.
Walker BA; Wardell CP; Melchor L; Brioli A; Johnson DC; Kaiser MF; Mirabella F; Lopez-Corral L; Humphray S; Murray L; Ross M; Bentley D; Gutiérrez NC; Garcia-Sanz R; San Miguel J; Davies FE; Gonzalez D; Morgan GJ
Leukemia; 2014 Feb; 28(2):384-390. PubMed ID: 23817176
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of hepatocyte growth factor, syndecan-1, and osteopontin in multiple myeloma and monoclonal gammopathy of undetermined significance.
Minarik J; Pika T; Bacovsky J; Petrova P; Langova K; Scudla V
ScientificWorldJournal; 2012; 2012():356128. PubMed ID: 22629140
[TBL] [Abstract][Full Text] [Related]
24. Global gene expression profiling in mouse plasma cell tumor precursor and bystander cells reveals potential intervention targets for plasma cell neoplasia.
LeGrand J; Park ES; Wang H; Gupta S; Owens JD; Nelson PJ; DuBois W; Bair T; Janz S; Mushinski JF
Blood; 2012 Jan; 119(4):1018-28. PubMed ID: 22147894
[TBL] [Abstract][Full Text] [Related]
25. Biological aspects of angiogenesis in multiple myeloma.
Otjacques E; Binsfeld M; Noel A; Beguin Y; Cataldo D; Caers J
Int J Hematol; 2011 Dec; 94(6):505-18. PubMed ID: 22086206
[TBL] [Abstract][Full Text] [Related]
26. Angiogenesis and multiple myeloma.
Giuliani N; Storti P; Bolzoni M; Palma BD; Bonomini S
Cancer Microenviron; 2011 Dec; 4(3):325-37. PubMed ID: 21735169
[TBL] [Abstract][Full Text] [Related]
27. Inducible expression of Runx2 results in multiorgan abnormalities in mice.
He N; Xiao Z; Yin T; Stubbs J; Li L; Quarles LD
J Cell Biochem; 2011 Feb; 112(2):653-65. PubMed ID: 21268087
[TBL] [Abstract][Full Text] [Related]
28. RARalpha2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma.
Wang S; Tricot G; Shi L; Xiong W; Zeng Z; Xu H; Zangari M; Barlogie B; Shaughnessy JD; Zhan F
Blood; 2009 Jul; 114(3):600-7. PubMed ID: 19458357
[TBL] [Abstract][Full Text] [Related]
29. Osteopontin expression correlates with angiogenesis and survival in malignant astrocytoma.
Matusan-Ilijas K; Behrem S; Jonjic N; Zarkovic K; Lucin K
Pathol Oncol Res; 2008 Sep; 14(3):293-8. PubMed ID: 18493866
[TBL] [Abstract][Full Text] [Related]
30. Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer.
Bellahcène A; Castronovo V; Ogbureke KU; Fisher LW; Fedarko NS
Nat Rev Cancer; 2008 Mar; 8(3):212-26. PubMed ID: 18292776
[TBL] [Abstract][Full Text] [Related]
31. Extravasation and homing mechanisms in multiple myeloma.
Vande Broek I; Vanderkerken K; Van Camp B; Van Riet I
Clin Exp Metastasis; 2008; 25(4):325-34. PubMed ID: 17952614
[TBL] [Abstract][Full Text] [Related]
32. Regulation and functional role of the Runt-related transcription factor-2 in pancreatic cancer.
Kayed H; Jiang X; Keleg S; Jesnowski R; Giese T; Berger MR; Esposito I; Löhr M; Friess H; Kleeff J
Br J Cancer; 2007 Oct; 97(8):1106-15. PubMed ID: 17876328
[TBL] [Abstract][Full Text] [Related]
33. The involvement of osteopontin and its receptors in multiple myeloma cell survival, migration and invasion in the murine 5T33MM model.
Caers J; Günthert U; De Raeve H; Van Valckenborgh E; Menu E; Van Riet I; Van Camp B; Vanderkerken K
Br J Haematol; 2006 Feb; 132(4):469-77. PubMed ID: 16412019
[TBL] [Abstract][Full Text] [Related]
34. Role of interleukin 16 in multiple myeloma.
Atanackovic D; Hildebrandt Y; Templin J; Cao Y; Keller C; Panse J; Meyer S; Reinhard H; Bartels K; Lajmi N; Sezer O; Zander AR; Marx AH; Uhlig R; Zustin J; Bokemeyer C; Kröger N
J Natl Cancer Inst; 2012 Jul; 104(13):1005-20. PubMed ID: 22745469
[TBL] [Abstract][Full Text] [Related]
35. [Link between osteoclastogenesis, angiogenesis and myeloma expansion].
Abe M
Clin Calcium; 2008 Apr; 18(4):473-9. PubMed ID: 18379029
[TBL] [Abstract][Full Text] [Related]
36. Osteopontin: a bridge between bone and blood.
Haylock DN; Nilsson SK
Br J Haematol; 2006 Sep; 134(5):467-74. PubMed ID: 16848793
[TBL] [Abstract][Full Text] [Related]
37. Human myeloma cells express the bone regulating gene Runx2/Cbfa1 and produce osteopontin that is involved in angiogenesis in multiple myeloma patients.
Colla S; Morandi F; Lazzaretti M; Rizzato R; Lunghi P; Bonomini S; Mancini C; Pedrazzoni M; Crugnola M; Rizzoli V; Giuliani N
Leukemia; 2005 Dec; 19(12):2166-76. PubMed ID: 16208410
[TBL] [Abstract][Full Text] [Related]
38. Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma.
Standal T; Hjorth-Hansen H; Rasmussen T; Dahl IM; Lenhoff S; Brenne AT; Seidel C; Baykov V; Waage A; Børset M; Sundan A; Hjertner O
Haematologica; 2004 Feb; 89(2):174-82. PubMed ID: 15003892
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
